Valion Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $3.92M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | $-2.23 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | $146.00K | $-1.97 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $86.00K | $-2.19 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | $-2.52 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 21, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | $126.00K | $-0.23 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | $140.00K | $-0.32 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 25, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | After market close | – | – | – |
Press releases
Announcements Valion Bio filed with the SEC
PRESS RELEASE, DATED OCTOBER 15, 2026
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED OCTOBER 14, 2026
Other events · EX-99.1 to Form 8-K
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
Other events · EX-99.1 to Form 8-K
Valion Bio and Shear Kershman Laboratories
Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED SEPTEMBER 23, 2026.
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Valion Bio Announces Changes to Management
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SAN ANTONIO, TX – August 27,
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Valion Bio Advances Integrated Biodefense
Regulation FD disclosure · EX-99.1 to Form 8-K
Valion Bio Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Valion Bio Appoints Melinda Lackey
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Reports Full Year 2025 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The Radiation Issue Ionizing radiation destroys fast - growing cells
Regulation FD disclosure · EX-99.1 to Form 8-K
Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package
Material agreement · Agreement terminated · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
FOR ENTOLIMOD ™ FOR ACUTE RADIATION SYNDROME
Other events · EX-99.1 to Form 8-K
Tivic Reports Third Quarter 2025 Financial Results
Results of operations · Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Health Reports Findings of Clinical
Other events · EX-99.1 to Form 8-K
Tivic Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Health Completes Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device
Regulation FD disclosure · EX-99.1 to Form 8-K
Looking forward, a reinvented company Immunotherapy Market Valued at $182.5B 2023, 10.4%CAGR Bioelectronic Immunomodulation via neurologic pathways Biologic Immunomodulation via molecular pathways (1) Immunotherapy Drugs Market Size, https://www.gminsights.com/industry-analysis/immunotherapy-drug…
Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Health Systems, Inc. Regains Compliance with NASDAQ
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Tivic Reports Year End 2024 Financial Results and Provides
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Looking forward, a reinvented company Complementary modalities create unique therapeutic pipeline Bioelectronic Devices that can reset a hyperactive immune system via neural pathways Biologic Drugs that can stimulate a hypoactive immune system through validated molecular pathways
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Tivic Health and Feinstein Institute Present New Data Showing
Other events · EX-99.1 to Form 8-K
Tivic Health Systems, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
TIVIC HEALTH NAMES BIOTECH INDUSTRY VETERAN MICHAEL K. HANDLEY
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Health Acquires Exclusive Worldwide Rights to
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
SHAREHOLDERS ISSUED BY TIVIC HEALTH
Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Health Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment
Other events · EX-99.1 to Form 8-K
Tivic Health Accelerates VNS Commercial Strategy Development
Other events · EX-99.1 to Form 8-K
Tivic Health Appoints Lisa Wolf as Interim Chief Financial Officer
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Health: Christina Valauri Appointed to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Tivic Health Partners with the Feinstein Institutes to Advance its Patent-pending, Non-Invasive Cervical Vagus Nerve Stimulation; Begins Optimization of ncVNS for use in Clinical Indications
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
NASDAQ TIVC INVESTOR PRESENTATION 2022 SEPT The future of medicine is electronic. NASDAQ : TIVC INVESTOR PRESENTATION May 2024
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K